Type 1 diabetes - Does suppressing T cells increase insulin?

New England Journal of Medicine

Volumn 352, Issue 25, 2005, Pages 2642-2644

  Lernmark, Åke ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYCLOSPORIN; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN G1; INSULIN; INTERLEUKIN 2 RECEPTOR ALPHA; NICOTINAMIDE; T LYMPHOCYTE RECEPTOR; ANTIDIABETIC AGENT; AUTOANTIBODY; CD3 ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

CELL FUNCTION; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; EDITORIAL; GENETIC RISK; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL ASSESSMENT; MEDICAL LITERATURE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; IMMUNOLOGY; NOTE; PANCREAS ISLET;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN G; INSULIN; ISLETS OF LANGERHANS;

EID: 20544459303     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058114     Document Type: Editorial

References (15)

1. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608.
2. Kent SC, Chen Y, Bregoli L, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005;435:224-8.
3. Krischer JP, Cuthbertson DD, Yu L, et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003;88:103-8.
4. Falorni A, Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 2005;19:119-33.
5. Notkins AL, Lernmark Å. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001;108:1247-52.
6. Pundziute-Lycka A, Dahlquist G, Nystrom L, et al. The incidence of type I diabetes has not increase but shifted to a younger age at diagnosis in the 0-34 years group in Sweden 1983-1998. Diabetologia 2002;45:783-91.
7. Skyler JS, Marks JB. Immune intervention in type 1 diabetes mellitus. Diabetes Rev 1993;1:15-42.
8. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988;37:1574-82.
9. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type 1 diabetes in children treated with cyclosporine. N Engl J Med 1988;318:663-70.
10. Parving HH, Tarnow L, Nielsen FS, et al. Cyclosporine nephrotoxicity in type 1 diabetic patients: a 7-year follow-up study. Diabetes Care 1999;22:478-83.
11. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
12. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-31.
13. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8.
14. Graham J, Hagopian WA, Kockum I, et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002;51:1346-55.
15. Agardh CD, Corrado CM, Lethagen Å, et al. Clinical evidence for safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications (in press).